Acquired by Johnson & Johnson in December 2022
ABMD - Abiomed, Inc.
NASDAQ
->
Healthcare
->
Medical Devices
Danvers,
United States
Type: Equity
ABMD price evolution
ABMD
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $182.34 | $180.49 | $132.82 | $144.25 |
| Short term investments | $638.04 | $663.83 | $625.79 | $524.97 |
| Net receivables | $94.47 | $91.1 | $90.61 | $88.95 |
| Inventory | $102.24 | $95.37 | $93.98 | $90.2 |
| Total current assets | $1062.8 | $1060.36 | $976.47 | $885.01 |
| Long term investments | $116.87 | $159.88 | $220.09 | $262.63 |
| Property, plant & equipment | $195.16 | $198.48 | $202.49 | $196.88 |
| Goodwill & intangible assets | $109.79 | $113.02 | $116.3 | $117.73 |
| Total noncurrent assets | $633.75 | $643.28 | $696.92 | $707.87 |
| Total investments | $754.91 | $823.71 | $845.88 | $787.6 |
| Total assets | $1696.54 | $1703.64 | $1673.39 | $1592.88 |
| Current liabilities | ||||
| Accounts payable | $35.07 | $34.8 | $35.35 | $32.07 |
| Deferred revenue | $25.96 | $23.62 | $26.36 | $24.87 |
| Short long term debt | ||||
| Total current liabilities | $134.06 | $140.76 | $138.46 | $126.8 |
| Long term debt | ||||
| Total noncurrent liabilities | $22.7 | $26.68 | $31.61 | $33.14 |
| Total debt | ||||
| Total liabilities | $156.76 | $167.44 | $170.07 | $159.94 |
| Shareholders' equity | ||||
| Retained earnings | $1125.2 | $1019.07 | $964.51 | $904.19 |
| Other shareholder equity | -$46.65 | -$38.27 | -$27.16 | -$20.49 |
| Total shareholder equity | $1539.79 | $1536.2 | $1503.33 | $1432.94 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $132.82 | $232.71 | $192.34 | $121.02 |
| Short term investments | $625.79 | $350.99 | $250.78 | $370.68 |
| Net receivables | $90.61 | $97.18 | $84.65 | $90.81 |
| Inventory | $93.98 | $81.06 | $90.09 | $80.94 |
| Total current assets | $976.47 | $787.97 | $635.86 | $677.2 |
| Long term investments | $220.09 | $264.08 | $207.79 | $21.72 |
| Property, plant & equipment | $202.49 | $197.13 | $164.93 | $145 |
| Goodwill & intangible assets | $116.3 | $120.72 | $31.97 | $32.6 |
| Total noncurrent assets | $696.92 | $706.39 | $580.6 | $377.15 |
| Total investments | $845.88 | $615.07 | $458.57 | $392.39 |
| Total assets | $1673.39 | $1494.36 | $1216.46 | $1054.35 |
| Current liabilities | ||||
| Accounts payable | $35.35 | $34.84 | $32.77 | $32.19 |
| Deferred revenue | $26.36 | $24.32 | $19.15 | $16.39 |
| Short long term debt | ||||
| Total current liabilities | $138.46 | $128.97 | $131.88 | $106 |
| Long term debt | ||||
| Total noncurrent liabilities | $31.61 | $35.72 | $19.11 | $11.46 |
| Total debt | $12.22 | |||
| Total liabilities | $170.07 | $164.68 | $151 | $117.46 |
| Shareholders' equity | ||||
| Retained earnings | $964.51 | $828.01 | $602.48 | $399.47 |
| Other shareholder equity | -$27.16 | -$11.45 | -$11.19 | -$14.69 |
| Total shareholder equity | $1503.33 | $1329.67 | $1065.47 | $936.89 |
| (in millions $) | 30 Oct 2022 | 30 Jun 2022 | 1 May 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $277.15 | $261.18 | ||
| Cost of revenue | $52.63 | $47.63 | ||
| Gross Profit | $224.52 | $213.55 | ||
| Operating activities | ||||
| Research & development | $40.48 | $40.87 | ||
| Selling, general & administrative | $118 | $107.62 | ||
| Total operating expenses | $158.47 | $148.98 | ||
| Operating income | $66.05 | $64.57 | ||
| Income from continuing operations | ||||
| EBIT | $69.82 | $57.88 | ||
| Income tax expense | $15.27 | $12.13 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | $54.55 | $45.75 | ||
| Income (for common shares) | $54.55 | $45.75 | ||
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1031.75 | $847.52 | $840.88 | $769.43 |
| Cost of revenue | $188.16 | $161.91 | $151.31 | $129.57 |
| Gross Profit | $843.6 | $685.62 | $689.58 | $639.87 |
| Operating activities | ||||
| Research & development | $163.4 | $121.88 | $98.76 | $93.5 |
| Selling, general & administrative | $423.49 | $334.18 | $341.6 | $321.55 |
| Total operating expenses | $702.88 | $456.06 | $440.36 | $415.05 |
| Operating income | $140.72 | $229.56 | $249.22 | $224.81 |
| Income from continuing operations | ||||
| EBIT | $190.56 | $288.22 | $256.82 | $263.36 |
| Income tax expense | $54.05 | $62.7 | $53.82 | $4.34 |
| Interest expense | ||||
| Net income | ||||
| Net income | $136.5 | $225.53 | $203.01 | $259.02 |
| Income (for common shares) | $136.5 | $225.53 | $203.01 | $259.02 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | $106.13 | $54.55 | $60.33 | $45.75 |
| Operating activities | ||||
| Depreciation | $6.72 | $6.62 | $7.29 | $6.93 |
| Business acquisitions & disposals | $39.99 | |||
| Stock-based compensation | $16.01 | $13.36 | $11.99 | $12.38 |
| Total cash flows from operations | $13.42 | $68.1 | $78.97 | $90.49 |
| Investing activities | ||||
| Capital expenditures | -$5.61 | -$6.78 | -$14.89 | -$6.48 |
| Investments | $67.18 | $14.9 | -$77.68 | -$173.54 |
| Total cash flows from investing | $101.57 | $8.11 | -$92.57 | -$180.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$108.33 | -$12.99 | $4.88 | $0.44 |
| Net borrowings | ||||
| Total cash flows from financing | -$110.18 | -$23.94 | $4.75 | -$6.16 |
| Effect of exchange rate | -$2.96 | -$4.61 | -$2.58 | -$1.93 |
| Change in cash and equivalents | $1.84 | $47.67 | -$11.44 | -$97.63 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | $136.5 | $225.53 | $203.01 | $259.02 |
| Operating activities | ||||
| Depreciation | $28.09 | $24.1 | $20.43 | $14.12 |
| Business acquisitions & disposals | -$82.82 | $15.7 | ||
| Stock-based compensation | $52.73 | $47.01 | $39.78 | $54.49 |
| Total cash flows from operations | $285.39 | $274.58 | $314.92 | $252.2 |
| Investing activities | ||||
| Capital expenditures | -$35.76 | -$53.38 | -$44.01 | -$44 |
| Investments | -$262.41 | -$185.66 | -$81.45 | -$72.45 |
| Total cash flows from investing | -$380.99 | -$223.34 | -$125.45 | -$116.45 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $16.66 | $3.24 | -$76.03 | $16 |
| Net borrowings | ||||
| Total cash flows from financing | -$2.2 | -$8.07 | -$117.72 | -$55.77 |
| Effect of exchange rate | -$2.09 | -$2.8 | -$0.43 | -$1.92 |
| Change in cash and equivalents | -$99.89 | $40.37 | $71.32 | $78.05 |
News
|
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
MSN News
27 Dec 2022
|
|
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
Zacks via Yahoo Finance
22 Dec 2022
|
|
A Look At Abiomed Before The $380/Share Buyout From JNJ (ABMD)
Seeking Alpha
22 Dec 2022
|
|
Abiomed Inc. stock rises Wednesday, still underperforms market
Market Watch
22 Dec 2022
|
|
Abiomed Inc. stock underperforms Monday when compared to competitors despite daily gains
Market Watch
20 Dec 2022
|
|
The 3 Safest Stocks to Buy in the Market Now
Entrpreneur
19 Dec 2022
|
|
3 Stocks to Buy That Could Make You a Millionaire in the Long Term
Entrpreneur
16 Dec 2022
|
|
Abiomed Inc. stock falls Monday, underperforms market
Market Watch
12 Dec 2022
|
|
Amgen Agrees to Acquire Horizon Therapeutics for $27.8 Billion
The Wall Street Journal
12 Dec 2022
|
|
4 Stocks That Can Weather Any Market Storm
Entrpreneur
9 Dec 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 45.17M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 35.12 |
| Cash/Share | 4.04 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.11 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.93 |
| Quick ratio | 7.17 |